Drugs for Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 90)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Acetylcysteine |
Approved, Investigational |
Phase 2 |
|
616-91-1 |
581 12035 |
Synonyms:
(2R)-2-ACETAMIDO-3-SULFANYLPROPANOIC ACID
(2R)-2-Acetylamino-3-sulfanylpropanoate
(2R)-2-Acetylamino-3-sulfanylpropanoic acid
(2R)-2-Acetylamino-3-sulphanylpropanoate
(2R)-2-Acetylamino-3-sulphanylpropanoic acid
(R)-2-Acetylamino-3-mercaptopropanoate
(R)-2-Acetylamino-3-mercaptopropanoic acid
(R)-Mercaptate
(R)-Mercaptic acid
(R)-Mercapturic acid
2-[(1-Hydroxyethylidene)amino]-3-sulfanylpropanoate
2-[(1-Hydroxyethylidene)amino]-3-sulphanylpropanoate
2-[(1-Hydroxyethylidene)amino]-3-sulphanylpropanoic acid
2-acetylamino-3-mercapto-Propionate
2-acetylamino-3-mercapto-Propionic acid
5052
Ac pharma brand OF acetylcysteine
ACC
ACC-600
Acebraus
Acemuc
Acetabs
Acetadote
Acetilcisteina
Acetylcystein al
Acetylcystein atid
Acetylcystein heumann
Acetylcystein trom
Acetylcystein, mentopin
Acetylcysteine
Acetylcysteine ac-pharma brand
Acetylcysteine alcon brand
Acetylcysteine aluid brand
Acetylcysteine atid brand
Acetylcysteine azupharma brand
Acetylcysteine betapharm brand
Acetylcysteine bioiberica brand
Acetylcysteine bouchara brand
Acetylcysteine centrafarm brand
Acetylcysteine disphar brand
Acetylcysteine farmasan brand
Acetylcysteine fresenius brand
Acetylcysteine génévrier brand
Acétylcystéine GNR
Acetylcysteine GNR-pharma brand
Acetylcysteine guerbet brand
Acetylcysteine hermes brand
Acetylcysteine heumann brand
Acetylcysteine hydrochloride
Acetylcysteine inpharzam brand
Acetylcysteine intra brand
Acetylcysteine klinge brand
Acetylcysteine krewel brand
Acetylcysteine lichtenstein brand
Acetylcysteine lindopharm brand
Acetylcysteine merck brand
Acetylcysteine oberlin brand
Acetylcysteine pfleger brand
Acetylcysteine pharbita brand
Acetylcysteine roberts brand
Acetylcysteine sodium
Acetylcysteine temmler brand
Acetylcysteine teva brand
Acetylcysteine thiemann brand
Acetylcysteine trommsdorff brand
Acetylcysteine upsa brand
Acetylcysteine whitehall brand
Acetylcysteine zambon brand
Acetylcysteine zinc
Acetylcysteine zyma brand
Acetylcysteine, (D)-isomer
Acetylcysteine, (DL)-isomer
Acetylcysteine, monoammonium salt
Acetylcysteine, monosodium salt
Acetylcysteinum
Acetylin
Acetyst
Acid, mercapturic
Ac-pharma brand OF acetylcysteine
A-CYS
Airbron
Alcon brand OF acetylcysteine
Allen and hanburys brand OF acetylcysteine
Aluid brand OF acetylcysteine
Alveolex
Atid brand OF acetylcysteine
Azubronchin
Azupharma brand OF acetylcysteine
Betapharm brand OF acetylcysteine
Bioiberica brand OF acetylcysteine
Bisolvon nac
Boehringer ingelheim brand OF acetylcysteine
Bouchara brand OF acetylcysteine
Bristol myers squibb brand OF acetylcysteine
Bristol myers squibb brand OF acetylcysteine sodium salt
Bristol-myers squibb brand OF acetylcysteine
Bristol-myers squibb brand OF acetylcysteine sodium salt
Bromuc
broncho Fips
broncho-Fips
BronchoFips
Broncholysin
Broncoclar
Centrafarm brand OF acetylcysteine
CETYLEV
Codotussyl
Cystamucil
dampo Mucopect
|
Dey brand OF acetylcysteine sodium salt
Disphar brand OF acetylcysteine
Durabronchal
EN-CYS
Eurespiran
Exomuc
Fabrol
Farmasan brand OF acetylcysteine
Fluimicil infantil
Fluimucetin
Fluimucil
FLUIMUCIL 600
FLUIMUCIL LONG
FLUIMUCIL N
Flumucetin
Fluprowit
Frekatuss
Fresenius brand OF acetylcysteine
Genac
Génévrier brand OF acetylcysteine
GNR Pharma brand OF acetylcysteine
GNR-Pharma brand OF acetylcysteine
Guerbet brand OF acetylcysteine
Hermes brand OF acetylcysteine
Heumann brand OF acetylcysteine
Hoestil
Hustengetränk, optipect
Hydrochloride, acetylcysteine
Ilube
Inpharzam brand OF acetylcysteine
Intra brand OF acetylcysteine
Jenacystein
Jenapharm
Klinge brand OF acetylcysteine
Krewel brand OF acetylcysteine
L-a-Acetamido-b-mercaptopropionate
L-a-Acetamido-b-mercaptopropionic acid
L-Acetylcysteine
L-alpha-Acetamido-beta-mercaptopropionate
L-alpha-Acetamido-beta-mercaptopropionic acid
Lantamed
Larylin nac
Lichtenstein brand OF acetylcysteine
Lindocetyl
Lindopharm brand OF acetylcysteine
Lysox
L-Α-acetamido-β-mercaptopropionate
L-Α-acetamido-β-mercaptopropionic acid
m Pectil
Mentopin acetylcystein
Mercaptate
Mercaptic acid
Mercapturic acid
Merck brand OF acetylcysteine
Monoammonium salt acetylcysteine
Monosodium salt acetylcysteine
m-Pectil
MPectil
Muciteran
muco Sanigen
Mucolysin
Mucomyst
Mucopect, dampo
Mucosil
MUCOSIL-10
MUCOSIL-20
Mucosol
Mucosolvin
N Acetyl L cysteine
N Acetylcysteine
NAC
NAC al
NAC zambon
NAC, bisolvon
N-Acetyl-3-mercaptoalanine
N-Acetylcysteine
N-Acety-L-cysteine
N-Acetyl-L-(+)-cysteine
N-Acetyl-L-cysteine
NSC-111180
Oberlin brand OF acetylcysteine
Optipect hustengetränk
ORONAC 600
PARVOLEX
Pfleger brand OF acetylcysteine
Pharbita brand OF acetylcysteine
Produpharm lappe brand OF acetylcysteine
RESPI-NAC
Roberts brand OF acetylcysteine
Roche nicholas brand OF acetylcysteine
Sanigen, muco
Siccoral
Siran
Sodium 2-acetamido-3-mercaptopropionate
Sodium, acetylcysteine
Solmucol
Temmler brand OF acetylcysteine
Teva brand OF acetylcysteine
Thiemann brand OF acetylcysteine
Trommsdorff brand OF acetylcysteine
UPSA brand OF acetylcysteine
Whitehall brand OF acetylcysteine
YOURNAC
Zambon brand OF acetylcysteine
Zambon, nac
Zinc, acetylcysteine
Zyma brand OF acetylcysteine
|
|
2 |
|
Vorinostat |
Approved, Investigational |
Phase 2 |
|
149647-78-9 |
5311 |
Synonyms:
18F Suberoylanilide hydroxamic acid
18F-SAHA
18F-Suberoylanilide hydroxamic acid
Merck brand OF vorinostat
MK0683
MK-0683
MK-0683|MK0683|SAHA|suberoylanilide hydroxamic acid|Zolinza®
N Hydroxy n' phenyloctanediamide
N1 Hydroxy N8 phenyloctanediamide
N1-Hydroxy-N8-phenyloctanediamide
NHNPODA
N-Hydroxy-n'-phenyloctanediamide
N-Hyrdroxy-n'-phenyloctanediamide
|
Octanedioate hydroxyamide phenylamide
Octanedioic acid hydroxyamide phenylamide
SAHA
SHH
Suberanilohydroxamate
Suberanilohydroxamic acid
Suberoyl anilide hydroxamic acid
Suberoylanilide hydroxamate
Suberoylanilide hydroxamic acid
VORINOSTAT
Vorinostatum
Zolinza
|
|
3 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
4 |
|
Bortezomib |
Approved, Investigational |
Phase 2 |
|
179324-69-7 |
387447 93860 |
Synonyms:
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID
341, PS
BORTEZOMIB
BORTEZOMIB HYDRATE
LDP 341
LDP-341
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
|
NSC-681239
PEPTIDE BORONATE
peptide boronate|PS-341|Velcade®
PS 341
PS-341
Velcade
|
|
5 |
|
Doxorubicin |
Approved, Investigational |
Phase 2 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
6 |
|
Cetuximab |
Approved |
Phase 1, Phase 2 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
7 |
|
Erlotinib |
Approved, Investigational |
Phase 1, Phase 2 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
8 |
|
Cisplatin |
Approved |
Phase 2 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
9 |
|
Lapatinib |
Approved, Investigational |
Phase 2 |
|
231277-92-2, 388082-78-8 |
208908 |
Synonyms:
FMM
FMM|GW 572016|GW572016|Tykerb®|Tyverb®
GSK-572016
GW 572016
GW-2016
GW572016
GW-572016
GW572016F
GW-572016F
GW-572016X
LAP016
LAPATINIB
LAPATINIB DITOLUENESULFONATE MONOHYDRATE
|
Lapatinib ditosylate
LAPATINIB DITOSYLATE MONOHYDRATE
Lapatinib tosilate hydrate
N-(3-Chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulphonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURANYL]-4-QUINAZOLINAMINE
Tycerb
Tykerb
TYVERB
|
|
10 |
|
Everolimus |
Approved |
Phase 2 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
11 |
|
Dasatinib |
Approved, Investigational |
Phase 2 |
|
302962-49-8 |
3062316 |
Synonyms:
(18F)-N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Anh. dasatinib
Anhydrous dasatinib
BMS 345825
BMS 345825|BMS 354825|BMS 35482513|Sprycel®
BMS 354825
BMS 35482513
BMS Dasatinib
BMS-354825
BMS-354825 HYDRATE
BMS-354825-03
|
DASATINIB
Dasatinib (anh.)
dasatinib (anhydrous)
DASATINIB ANHYDROUS
DASATINIB HYDRATE
DASATINIB MONOHYDRATE
Dasatinibum
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Sprycel
|
|
12 |
|
Dexrazoxane |
Approved, Withdrawn |
Phase 2 |
|
24584-09-6 |
71384 |
Synonyms:
(+)-(S)-4,4′-PROPYLENEDI-2,6-PIPERAZINEDIONE
(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione
(+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane
4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
ADR 529
ADR-529
Cardioxan
Cardioxane
Desrazoxane
Dexrazoxan
Dexrazoxane
Dexrazoxane hydrochloride
Dexrazoxano
Dexrazoxano [INN-Spanish]
Dexrazoxanum
Dexrazoxanum [INN-Latin]
Dextrorazoxane
|
DRX187
Dyzoxane
Eucardion
Hydrochloride, dexrazoxane
ICRF 187
Icrf-187
ICRF187
NSC-169780
Razoxana [INN-Spanish]
Razoxane
Razoxane, (S)-isomer
Razoxane, (S)-isomer, hydrochloride
Razoxanum [INN-Latin]
Razoxin
Tepirone
Troxozone
Zinecard
|
|
13 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
14 |
|
Gemcitabine |
Approved |
Phase 2 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
15 |
|
Nelfinavir |
Approved |
Phase 2 |
|
159989-64-7 |
64143 |
Synonyms:
1UN
AG1343
Agouron brand OF nelfinavir mesylate
Mesylate, nelfinavir
Monomethane sulfonate, nelfinavir
Nelfinavir
Nelfinavir mesylate
|
Nelfinavir monomethane sulfonate
NFV
NLF
Roche brand OF nelfinavir mesylate
Sulfonate, nelfinavir monomethane
Viracept
|
|
16 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
17 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
18 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
19 |
|
Axitinib |
Approved, Investigational |
Phase 2 |
|
319460-85-0 |
6450551 |
Synonyms:
AG 013736
AG 013736|AG-013736|AG013736|Inlyta®
AG013736
AG-013736
AG-13736
|
AXITINIB
AXITINIBUM
INLYTA
N-METHYL-2-({3-[(E)-2-(PYRIDIN-2-YL)VINYL]-1H-INDAZOL-6-YL}SULFANYL)BENZAMIDE
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
|
|
20 |
|
Avelumab |
Approved, Investigational |
Phase 2 |
|
1537032-82-8 |
|
Synonyms:
AVELUMAB
BAVENCIO
MSB0010682
|
|
|
21 |
|
Lenvatinib |
Approved, Investigational |
Phase 2 |
|
417716-92-8 |
9823820 |
Synonyms:
4-(3-chloro-4-((Cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
4-(3-Chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4-{3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOXY}-7-METHOXYQUINOLINE-6-CARBOXAMIDE
e 7080
E 7080|ER-203492-00|Kisplyx®|Lenvima®
e7080
E-7080
|
ER-203492-00
KISPLYX
LENVATINIB
LENVATINIB MESYLATE
Lenvima
UNII-ee083865g2
|
|
22 |
|
Aspartic acid |
Approved, Nutraceutical |
Phase 1, Phase 2 |
|
56-84-8 |
5960 |
Synonyms:
(+)-Aspartate
(+)-Aspartic acid
(+-)-Aspartic acid
(2S)-2-AMINOBUTANEDIOIC ACID
(2S)-2-AMINOSUCCINIC ACID
(2S)-Aspartate
(2S)-Aspartic acid
(L)-Aspartate
(L)-Aspartic acid
(R)-2-Aminosuccinate
(R,S)-Aspartic acid
(S)-(+)-Aspartate
(S)-(+)-Aspartic acid
(S)-2-Aminobutanedioate
(S)-2-Aminobutanedioic acid
(S)-2-Aminosuccinate
(S)-2-Aminosuccinic acid
(S)-Aminobutanedioate
(S)-Amino-butanedioate
(S)-Aminobutanedioic acid
(S)-Amino-butanedioic acid
(S)-Aspartate
(S)-Aspartic acid
[<sup>3</sup>H]-L-aspartate|[<sup>3</sup>H]-L-aspartic acid
2-Amino-3-methylsuccinate
2-Amino-3-methylsuccinic acid
2-Aminosuccinate
2-Aminosuccinic acid
ácido aspártico
Acidum asparticum
alpha-Aminosuccinate
alpha-Aminosuccinic acid
Aminosuccinate
Ammonium aspartate
Asp
Asparagate
Asparagic acid
Asparaginate
Asparaginic acid
Asparatate
ASPARTate
Aspartate magnesium hydrochloride
Aspartate, ammonium
Aspartate, calcium
Aspartate, dipotassium
Aspartate, disodium
Aspartate, magnesium
Aspartate, monopotassium
Aspartate, monosodium
Aspartate, potassium
Aspartate, sodium
|
ASPARTIC ACID
Aspartic acid, ammonium salt
Aspartic acid, calcium salt
Aspartic acid, dipotassium salt
Aspartic acid, disodium salt
Aspartic acid, hydrobromide
Aspartic acid, hydrochloride
Aspartic acid, magnesium (1:1) salt, hydrochloride, trihydrate
Aspartic acid, magnesium (2:1) salt
Aspartic acid, magnesium-potassium (2:1:2) salt
Aspartic acid, monopotassium salt
Aspartic acid, monosodium salt
Aspartic acid, potassium salt
Aspartic acid, sodium salt
Calcium aspartate
D
Dipotassium aspartate
Disodium aspartate
FEMA NO. 3656
H-Asp-OH
Hydrobromide aspartic acid
Hydrochloride aspartic acid
Hydrochloride, aspartate magnesium
L Aspartate
L Aspartic acid
L-(+)-Aspartate
L-(+)-Aspartic acid
L-Aminosuccinate
L-Aminosuccinic acid
L-Asp
L-Asp|L-aspartate
L-Asparagate
L-Asparagic acid
L-Asparaginate
L-Asparaginic acid
L-Asparaginsaeure
L-Asparaginsäure
L-Aspartate
L-Aspartic acid
Magnesiocard
Magnesium aspartate
MG 5 Longoral
MG5Longoral
MG-5-Longoral
Monopotassium aspartate
Monosodium aspartate
NSC-3973
Poly-DL-succinimide
Polysuccinimide
Potassium aspartate
Sodium aspartate
|
|
23 |
|
Arginine |
Approved, Investigational, Nutraceutical |
Phase 1, Phase 2 |
|
74-79-3 |
6322 |
Synonyms:
(2S)-2-Amino-5-(carbamimidamido)pentanoate
(2S)-2-Amino-5-(carbamimidamido)pentanoic acid
(2S)-2-AMINO-5-(DIAMINOMETHYLIDENEAMINO)PENTANOIC ACID
(2S)-2-AMINO-5-[(DIAMINOMETHYLIDENE)AMINO]PENTANOIC ACID
(2S)-2-Amino-5-guanidinopentanoate
(2S)-2-Amino-5-guanidinopentanoic acid
(2S)-2-AMINO-5-GUANIDINO-PENTANOIC ACID
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoic acid
(S)-2-Amino-5-guanidinopentanoate
(S)-2-Amino-5-guanidinopentanoic acid
(S)-2-Amino-5-guanidinovalerate
(S)-2-Amino-5-guanidinovaleric acid
2-Amino-5-guanidinovalerate
2-Amino-5-guanidinovaleric acid
5-[(Aminoiminomethyl)amino]-L-norvaline
Arg
Arginina
Arginine
|
Arginine hydrochloride
Arginine, L isomer
Arginine, L-isomer
DL Arginine acetate, monohydrate
DL-Arginine acetate, monohydrate
Hydrochloride, arginine
L Arginine
L-(+)-Arginine
L-a-Amino-D-guanidinovalerate
L-a-Amino-D-guanidinovaleric acid
L-alpha-Amino-delta-guanidinovalerate
L-alpha-Amino-delta-guanidinovaleric acid
L-Arg
L-Arginin
L-ARGININE
L-Isomer arginine
Monohydrate DL-arginine acetate
N5-(Aminoiminomethyl)-L-ornithine
NSC-206269
R
|
|
24 |
|
Glycine |
Approved, Nutraceutical, Vet_approved |
Phase 1, Phase 2 |
|
56-40-6 |
750 |
Synonyms:
[<sup>14</sup>C]-glycine
2-Aminoacetate
2-Aminoacetic acid
Acid, aminoacetic
Aciport
Aminoacetate
Amino-acetate
Amino-acetic acid
AMINOACETIC ACID
AMINOESSIGSAEURE
AMINOESSIGSÄURE
Aminoethanoate
AMINOETHANOIC ACID
Calcium salt glycine
Cobalt salt glycine
Copper salt glycine
FEMA NO. 3287
G
Glicina
Glicoamin
GLY
GLYCIN
GLYCINE
Glycine carbonate (1:1), monosodium salt
Glycine carbonate (2:1), monolithium salt
Glycine carbonate (2:1), monopotassium salt
Glycine carbonate (2:1), monosodium salt
Glycine hydrochloride
Glycine hydrochloride (2:1)
Glycine phosphate
|
Glycine phosphate (1:1)
Glycine sulfate (3:1)
Glycine, calcium salt
Glycine, calcium salt (2:1)
Glycine, cobalt salt
Glycine, copper salt
Glycine, monoammonium salt
Glycine, monopotasssium salt
Glycine, monosodium salt
Glycine, sodium hydrogen carbonate
GLYCOCOLL
GLYCOLIXIR
Glycosthene
GLYKOKOLL
GLYZIN
Gyn-hydralin
H2N-CH2-COOH
HGLY
Hydrochloride, glycine
LEIMZUCKER
Monoammonium salt glycine
Monopotasssium salt glycine
Monosodium salt glycine
NSC-25936
Padil
Phosphate, glycine
Salt glycine, monoammonium
Salt glycine, monosodium
جلايسين
|
|
25 |
|
Isotretinoin |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
302-79-4, 4759-48-2 |
5538 444795 5282379 |
Synonyms:
(13-cis)-Retinoate
(13-CIS)-RETINOIC ACID
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXENYL)NONA-2,4,6,8-TETRAENOIC ACID
(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate
(2Z,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAENOIC ACID
(7E,9E,11E,13Z)-Retinoate
(7E,9E,11E,13Z)-RETINOIC ACID
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
13 cis Retinoic acid
13 CIS-RETINOIC ACID
13-cis-Retinoate
13-cis-Retinoate,isotretinoin
13-CIS-RETINOIC ACID
13-CIS-VITAMIN A ACID
13-RA
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoate (ecl)
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
Aberel
ABSORICA
ACCUTANE
Acid, all-trans-retinoic
Acid, beta-all-trans-retinoic
Acid, retinoic
Acid, trans-retinoic
Acid, vitamin a
Acide retinoique
ACIDE RETINOIQUE (FRENCH)
ACIDE RETINOIQUE (FRENCH) (DSL)
ACTICIN
AGN 100335
Airol
Aknefug
Aknoten
all trans Retinoic acid
all trans-Retinoic acid
all-(e)-Retinoate
all-(e)-Retinoic acid
all-trans-beta-Retinoate
all-trans-beta-Retinoic acid
all-trans-b-Retinoate
all-trans-b-Retinoic acid
all-trans-Retinoate
all-trans-Retinoic acid
ALL-TRANS-RETINOIC ACID (ATRA)
all-trans-retinoic acid (ATRA)|Altreno® (0.05% lotion)|Avita® (0.025% gel)|Renova® (0.02% cream)
all-trans-Tretinoin
all-trans-Vitamin a acid
all-trans-Vitamin a1 acid
all-trans-Β-retinoate
all-trans-Β-retinoic acid
ALTRENO
AMNESTEEM
ATRA
Atra-IV
Atralin
Avita
beta all trans Retinoic acid
beta-all-trans-Retinoic acid
beta-Retinoate
beta-Retinoic acid
b-Retinoate
b-Retinoic acid
CIP-isotretinoin
CIS-RA
cis-Retinoate
|
CIS-RETINOIC ACID
CLARAVIS
Dermairol
Eudyna
ISOTRETINOIN
Isotretinoin zinc salt, 13 cis isomer
Isotretinoin zinc salt, 13-cis-isomer
Isotretinoina
Isotretinoína
Isotretinoine
Isotrétinoine
Isotretinoino
Isotretinoinum
ISOTREX
Lsotretinoin
MYORISAN
NEOVITAMIN A ACID
NSC-122758
PAT-001
Potassium salt, tretinoin
Renova
Retin a
Retin-a
Retin-a micro
RETIN-A-MICRO
Retinoate
Retinoic acid
RETINOIC ACID 13-CIS-FORM
Retionic acid
Retisol-a
Ro 1-5488
RO-43780
RO-4-3780
Roaccutan
ROACCUTANE
Roacutan
Salt, tretinoin potassium
Salt, tretinoin sodium
Salt, tretinoin zinc
Sodium salt, tretinoin
Solage
SOTRET
Stieva-a
Stieva-a Forte
Teriosal
trans Retinoic acid
trans-Retinoate
trans-Retinoic acid
Tretin m
Tretinoin
Tretinoin potassium salt
Tretinoin sodium salt
Tretinoin zinc salt
TRETINOIN、ATRA
Tretinoina
Trétinoïne
TRETINOINE (FRENCH)
TRETINOINE (FRENCH) (EINECS)
Tretinoinum
Tretin-X
Tri-Luma
Vesanoid
Vitamin a acid
Vitinoin
ZENATANE
Zinc salt, tretinoin
Β-retinoate
Β-retinoic acid
|
|
26 |
|
D-Tyrosine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2 |
|
133585-56-5, 60-18-4, 556-02-5 |
1153 6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-AMINO-3-(4-HYDROXYPHENYL)PROPIONIC ACID
(2S)-2-AZANYL-3-(4-HYDROXYPHENYL)PROPANOIC ACID
(R)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(R)-3-(p-Hydroxyphenyl)alanine
(S)-(-)-Tyrosine
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(4-hydroxyphenyl)propanoate
|
2-Amino-3-(4-hydroxyphenyl)propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionate
2-Amino-3-(p-hydroxyphenyl)propionic acid
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
4-hydroxy-L-phenylalanine
6-Hydroxysandoricin
Benzenepropanoate
Benzenepropanoic acid
D-Tyr
D-Tyrosin
FEMA NO. 3736
L Tyrosine
LEVODOPA IMPURITY, L-TYROSINE-
LEVODOPA RELATED COMPOUND L-TYROSINE
L-p-Tyrosine
L-Tyrosin
L-tyrosine
Methyl 2-[5,11-bis(acetyloxy)-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]-2-hydroxyacetic acid
NSC-82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Tirosina
Tyr
Tyrosin
Tyrosine
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Y
|
|
27 |
|
Rivoceranib |
Investigational |
Phase 2 |
|
811803-05-1 |
11315474 |
Synonyms:
APATINIB
apatinib (in China)|YN968D1
Apatinib mesylate
Rivoceranib
|
Rivoceranib mesylate
YN968D1
YN968D1 free base
|
|
28 |
|
Imatinib Mesylate |
|
Phase 2 |
|
220127-57-1 |
|
Synonyms:
GLEEVEC
GLIVEC
IMATINIB MESILATE
IMATINIB MESYLATE
|
IMATINIB METHANESULFONATE
STI571
STI-571
|
|
29 |
|
Antiviral Agents |
|
Phase 2 |
|
|
|
30 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
31 |
|
Expectorants |
|
Phase 2 |
|
|
|
32 |
|
Antidotes |
|
Phase 2 |
|
|
|
33 |
|
N-monoacetylcystine |
|
Phase 2 |
|
|
|
34 |
|
Respiratory System Agents |
|
Phase 2 |
|
|
|
35 |
|
Antioxidants |
|
Phase 2 |
|
|
|
36 |
|
Protective Agents |
|
Phase 2 |
|
|
|
37 |
|
Histone Deacetylase Inhibitors |
|
Phase 2 |
|
|
|
38 |
|
Immunoglobulins, Intravenous |
|
Phase 2 |
|
|
|
39 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
40 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
41 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
42 |
|
Liposomal doxorubicin |
|
Phase 2 |
|
|
|
43 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
44 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
45 |
|
Razoxane |
|
Phase 2 |
|
|
|
Synonyms:
(+,-)-1,2-Bis(3,5-dioxopiperazine-1-yl)propane
Cardioxane
ICI-59118
ICRF 159
ICRF 186
ICRF159
ICRF-159
ICRF186
|
ICRF-186
Razoxana
RAZOXANE
Razoxane mesylate, (R)-isomer
Razoxane, (R)-isomer
Razoxanum
Razoxin
|
|
46 |
|
Radiopharmaceuticals |
|
Phase 1, Phase 2 |
|
|
|
47 |
|
Antihypertensive Agents |
|
Phase 2 |
|
|
|
48 |
|
Neurotransmitter Agents |
|
Phase 1, Phase 2 |
|
|
|
49 |
|
Arginyl-glycyl-aspartic acid |
|
Phase 1, Phase 2 |
|
|
3328704 |
Synonyms:
2-({2-[(2-amino-5-carbamimidamido-1-hydroxypentylidene)amino]-1-hydroxyethylidene}amino)butanedioate
|
|
|
50 |
|
Fluorodeoxyglucose F18 |
|
Phase 1, Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 76)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland |
Unknown status |
NCT03146650 |
Phase 2 |
|
2 |
Phase II Study of Apatinib Mesylate Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck |
Unknown status |
NCT02775370 |
Phase 2 |
Apatinib Mesylate |
3 |
Phase II Study of Imatinib (Glivec) Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Overexpressing KIT |
Unknown status |
NCT00180921 |
Phase 2 |
Imatinib |
4 |
Combined Treatment of Adenoid Cystic Carcinoma With Cetuximab and IMRT Plus C12 Heavy Ion Boost - ACCEPT - (ACC, Erbitux, and Particle Therapy); Phase I/II Feasibility Study |
Unknown status |
NCT01192087 |
Phase 1, Phase 2 |
Cetuximab |
5 |
A Phase II Randomized Trial of Efficacy and Safety of Particle Therapy With or Without Apatinib as Induction Therapy for Treatment of Head and Neck Adenoid Cystic Carcinoma |
Unknown status |
NCT02942693 |
Phase 2 |
Apatinib |
6 |
Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety |
Unknown status |
NCT02883374 |
Phase 2 |
Chidamide |
7 |
A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies |
Completed |
NCT02123511 |
Phase 2 |
acetylcysteine |
8 |
A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) |
Completed |
NCT01175980 |
Phase 2 |
Vorinostat |
9 |
A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma |
Completed |
NCT01604772 |
Phase 2 |
Akt Inhibitor MK2206 |
10 |
A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage |
Completed |
NCT00492089 |
Phase 2 |
bevacizumab;placebo |
11 |
Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck |
Completed |
NCT00077428 |
Phase 2 |
bortezomib;doxorubicin hydrochloride |
12 |
A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma |
Completed |
NCT00101348 |
Phase 1, Phase 2 |
erlotinib hydrochloride |
13 |
A Phase II Study of DOVitinib in REcurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE) |
Completed |
NCT01678105 |
Phase 2 |
Dovitinib |
14 |
A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands |
Completed |
NCT00095563 |
Phase 2 |
lapatinib ditosylate |
15 |
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors |
Completed |
NCT00859937 |
Phase 2 |
Dasatinib |
16 |
A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma |
Completed |
NCT03087019 |
Phase 2 |
Pembrolizumab |
17 |
Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Head and Neck Adenoid Cystic Carcinoma |
Completed |
NCT00581360 |
Phase 2 |
doxorubicin and bortezomib |
18 |
A Phase 2 Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands |
Completed |
NCT00886132 |
Phase 2 |
Sunitinib |
19 |
Chidamide Combined With Cisplatin in Recurrent or Metastatic Head and Neck Adenoid Cystic Carcinoma: A Prospective, Open-label, Phase II Study of a Single Center |
Completed |
NCT03639168 |
Phase 2 |
Chidamide combined with cisplatin |
20 |
A Phase II Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma |
Completed |
NCT03999684 |
Phase 2 |
Tretinoin |
21 |
Phase II Study On Gemcitabine In Recurrent Or Metastatic Adenoid Cystic Carcinoma Of The Head And Neck |
Completed |
NCT00017498 |
Phase 2 |
gemcitabine hydrochloride |
22 |
A Phase II Pilot Study of Dovitinib (TKI258) in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. |
Completed |
NCT01524692 |
Phase 2 |
Dovitinib (TKI258) |
23 |
A Phase II Study of Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma |
Completed |
NCT01558661 |
Phase 2 |
AG-013736 (AXITINIB) |
24 |
Randomized Phase II Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma |
Completed |
NCT02859012 |
Phase 2 |
Axitinib |
25 |
Phase II Study of RAD001monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma |
Completed |
NCT01152840 |
Phase 2 |
RAD001 |
26 |
Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma |
Completed |
NCT01417143 |
Phase 2 |
TKI258 (Dovitinib): |
27 |
Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis |
Completed |
NCT01806675 |
Phase 1, Phase 2 |
18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2 |
28 |
A Phase II Trial of the HIV Protease Inhibitor Nelfinavir in Patients With Recurrent Symptomatic Adenoid Cystic Cancers of the Head and Neck |
Completed |
NCT01065844 |
Phase 2 |
Nelfinavir |
29 |
Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract |
Completed |
NCT02860936 |
Phase 2 |
Lenvatinib |
30 |
A Phase 2 Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma (ACC) |
Recruiting |
NCT03990571 |
Phase 2 |
Avelumab;Axitinib |
31 |
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation |
Recruiting |
NCT04214366 |
Phase 2 |
|
32 |
A Phase II Study of Lenvatinib Plus Pembrolizumab in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma and Other Salivary Gland Cancers |
Recruiting |
NCT04209660 |
Phase 2 |
Lenvatinib;Pembrolizumab |
33 |
A Prospective, Open-label, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of All-trans Retinoic Acid (ATRA) in the Treatment of Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck |
Recruiting |
NCT04433169 |
Phase 2 |
All-trans Retinoic Acid;VEGFR inhibitor;Chemotherapy |
34 |
Tyrosine Kinase Inhibitors in the Management of Local Advanced or Metastastic Adenoid Cystic Carcinoma |
Recruiting |
NCT04974866 |
Phase 2 |
EGFR-TK Inhibitor |
35 |
Phase II Study to Evaluate Amivantamab in Recurrent and Metastatic Adenoid Cystic Carcinoma |
Recruiting |
NCT05074940 |
Phase 2 |
Amivantamab |
36 |
Lutetium-177-PSMA Radioligand Therapy for Advanced Salivary Gland Cancer, a Phase II Pilot Study. |
Recruiting |
NCT04291300 |
Phase 2 |
Lutetium-177-PSMA-I&T |
37 |
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001) |
Recruiting |
NCT04140526 |
Phase 1, Phase 2 |
ONC-392;Pembrolizumab |
38 |
A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway |
Recruiting |
NCT03422679 |
Phase 1, Phase 2 |
CB-103 |
39 |
Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma |
Recruiting |
NCT05010629 |
Phase 2 |
9-ING-41;Carboplatin |
40 |
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
Recruiting |
NCT02834013 |
Phase 2 |
|
41 |
A Phase 2, Open-Label, Multi-center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations |
Active, not recruiting |
NCT03691207 |
Phase 2 |
AL101 |
42 |
A Phase II Study of Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma |
Active, not recruiting |
NCT02098538 |
Phase 2 |
Regorafenib |
43 |
A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin |
Active, not recruiting |
NCT04119453 |
Phase 2 |
Rivoceranib |
44 |
A Phase II Study of Lenvatinib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma |
Active, not recruiting |
NCT02780310 |
Phase 2 |
Lenvatinib |
45 |
Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma |
Withdrawn |
NCT04832438 |
Phase 2 |
9-ING-41;Carboplatin |
46 |
A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer |
Completed |
NCT00470496 |
Phase 1 |
HPPH;photodynamic therapy |
47 |
A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer |
Completed |
NCT00023959 |
Phase 1 |
hydroxyurea;fluorouracil |
48 |
A Phase I Trial of Herceptin and Interleukin-12 |
Completed |
NCT00004074 |
Phase 1 |
|
49 |
Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. |
Completed |
NCT00089362 |
Phase 1 |
alvespimycin hydrochloride |
50 |
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer |
Completed |
NCT00397384 |
Phase 1 |
cetuximab;erlotinib hydrochloride |
|